{"id":"https://openalex.org/W2029290656","doi":"https://doi.org/10.1097/00004850-200609000-00004","title":"Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat","display_name":"Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat","publication_year":2006,"publication_date":"2006-07-28","ids":{"openalex":"https://openalex.org/W2029290656","doi":"https://doi.org/10.1097/00004850-200609000-00004","mag":"2029290656","pmid":"https://pubmed.ncbi.nlm.nih.gov/16877897"},"language":"en","primary_location":{"id":"doi:10.1097/00004850-200609000-00004","doi":"https://doi.org/10.1097/00004850-200609000-00004","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004850-200609000-00004","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037167848","display_name":"John Cookson","orcid":"https://orcid.org/0000-0002-1057-8338","observed_orcids":["https://orcid.org/0000-0002-1057-8338"]},"institutions":[{"id":"https://openalex.org/I2801259928","display_name":"Royal London Hospital","ror":"https://ror.org/019my5047","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044","https://openalex.org/I2801259928"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John Cookson","raw_affiliation_strings":["Department of Psychiatry, The Royal London Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, The Royal London Hospital, London, UK","institution_ids":["https://openalex.org/I2801259928"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063639716","display_name":"Inmaculada Gilaberte","orcid":"https://orcid.org/0000-0002-3811-9811","observed_orcids":["https://orcid.org/0000-0002-3811-9811"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Inmaculada Gilaberte","raw_affiliation_strings":["Declaration of Interest: Inmaculada Gilaberte, Daniel Kajdasz, and Durisala Desaiah are employees and shareholders of Eli Lilly and Company. John Cookson is a member of advisory boards and speakers\u2019 panel for Eli Lilly and Company","Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Declaration of Interest: Inmaculada Gilaberte, Daniel Kajdasz, and Durisala Desaiah are employees and shareholders of Eli Lilly and Company. John Cookson is a member of advisory boards and speakers\u2019 panel for Eli Lilly and Company","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007350826","display_name":"Durisala Desaiah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Durisala Desaiah","raw_affiliation_strings":["Declaration of Interest: Inmaculada Gilaberte, Daniel Kajdasz, and Durisala Desaiah are employees and shareholders of Eli Lilly and Company. John Cookson is a member of advisory boards and speakers\u2019 panel for Eli Lilly and Company","Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Declaration of Interest: Inmaculada Gilaberte, Daniel Kajdasz, and Durisala Desaiah are employees and shareholders of Eli Lilly and Company. John Cookson is a member of advisory boards and speakers\u2019 panel for Eli Lilly and Company","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5091037144","display_name":"Daniel K. Kajdasz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Daniel K. Kajdasz","raw_affiliation_strings":["Declaration of Interest: Inmaculada Gilaberte, Daniel Kajdasz, and Durisala Desaiah are employees and shareholders of Eli Lilly and Company. John Cookson is a member of advisory boards and speakers\u2019 panel for Eli Lilly and Company","Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA","and requests for reprints to Dr Daniel Kajdasz, PhD, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Declaration of Interest: Inmaculada Gilaberte, Daniel Kajdasz, and Durisala Desaiah are employees and shareholders of Eli Lilly and Company. John Cookson is a member of advisory boards and speakers\u2019 panel for Eli Lilly and Company","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"and requests for reprints to Dr Daniel Kajdasz, PhD, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5091037144"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":null,"apc_paid":null,"fwci":1.7124,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.8299599,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"21","issue":"5","first_page":"267","last_page":"273"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10272","display_name":"Mental Health Treatment and Access","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duloxetine","display_name":"duloxetine","score":1.0},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9959999918937683},{"id":"https://openalex.org/keywords/number-needed-to-treat","display_name":"number needed to treat","score":0.9959999918937683},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.9750000238418579},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.9900000095367432},{"id":"https://openalex.org/keywords/fluoxetine","display_name":"fluoxetine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/paroxetine","display_name":"paroxetine","score":1.0},{"id":"https://openalex.org/keywords/remission","display_name":"remission","score":0.6890000104904175},{"id":"https://openalex.org/keywords/response","display_name":"response","score":0.5450000166893005},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.9330000281333923},{"id":"https://openalex.org/keywords/hamilton-depression-rating-scale","display_name":"Hamilton Depression Rating Scale","score":0.7699999809265137},{"id":"https://openalex.org/keywords/clinical-global-impression-scale","display_name":"Clinical Global Impression Scale","score":0.9490000009536743}],"concepts":[{"id":"https://openalex.org/C2780764818","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine","level":3,"score":0.958642840385437},{"id":"https://openalex.org/C67774102","wikidata":"https://www.wikidata.org/wiki/Q614132","display_name":"Number needed to treat","level":4,"score":0.8072493076324463},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.7338117361068726},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.6707241535186768},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.620936393737793},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.6021401882171631},{"id":"https://openalex.org/C2777828372","wikidata":"https://www.wikidata.org/wiki/Q408471","display_name":"Paroxetine","level":4,"score":0.5553553700447083},{"id":"https://openalex.org/C2910564767","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine Hydrochloride","level":4,"score":0.5179285407066345},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.501523494720459},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.4851115942001343},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.460602343082428},{"id":"https://openalex.org/C142454548","wikidata":"https://www.wikidata.org/wiki/Q7069573","display_name":"Number needed to harm","level":5,"score":0.450877845287323},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4197450578212738},{"id":"https://openalex.org/C2780092697","wikidata":"https://www.wikidata.org/wiki/Q7455053","display_name":"Serotonin reuptake inhibitor","level":4,"score":0.416729211807251},{"id":"https://openalex.org/C83849319","wikidata":"https://www.wikidata.org/wiki/Q7295720","display_name":"Rating scale","level":2,"score":0.4121185839176178},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3916488289833069},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.21302494406700134},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.12214627861976624},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.11520346999168396},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.10983586311340332},{"id":"https://openalex.org/C138496976","wikidata":"https://www.wikidata.org/wiki/Q175002","display_name":"Developmental psychology","level":1,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068736","descriptor_name":"Duloxetine Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017374","descriptor_name":"Paroxetine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00004850-200609000-00004","doi":"https://doi.org/10.1097/00004850-200609000-00004","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004850-200609000-00004","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:16877897","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16877897","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International clinical psychopharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W72273208","https://openalex.org/W1554277077","https://openalex.org/W1971393265","https://openalex.org/W1977927738","https://openalex.org/W1979917573","https://openalex.org/W1982721912","https://openalex.org/W1997685981","https://openalex.org/W2002764029","https://openalex.org/W2017285222","https://openalex.org/W2017766892","https://openalex.org/W2018645792","https://openalex.org/W2031385454","https://openalex.org/W2033209427","https://openalex.org/W2044804952","https://openalex.org/W2069090735","https://openalex.org/W2073434093","https://openalex.org/W2085375926","https://openalex.org/W2088302707","https://openalex.org/W2099564543","https://openalex.org/W2111149452","https://openalex.org/W2125669390","https://openalex.org/W2130365212","https://openalex.org/W2132966541","https://openalex.org/W2133710857","https://openalex.org/W2137946901","https://openalex.org/W2160008980","https://openalex.org/W2235189311","https://openalex.org/W3171418018","https://openalex.org/W4297952586"],"related_works":["https://openalex.org/W1969422647","https://openalex.org/W2103453698","https://openalex.org/W2274762642","https://openalex.org/W2000844006","https://openalex.org/W2137946901","https://openalex.org/W2003363634","https://openalex.org/W1994256806","https://openalex.org/W2158176267","https://openalex.org/W2051428213","https://openalex.org/W2159484656"],"abstract_inverted_index":{"The":[0,44,119,147,162,182,207,214],"efficacy":[1,53,71,220],"of":[2,20,46,54,58,74,88,117,171,219,228,233],"an":[3],"antidepressant":[4],"typically":[5],"is":[6,37,49],"assessed":[7],"by":[8,137,179],"comparing":[9],"it":[10],"with":[11,91,160,238],"placebo":[12],"using":[13],"a":[14,33,77],"validated":[15],"rating":[16],"scale.":[17],"This":[18],"type":[19],"analysis,":[21],"however,":[22],"does":[23],"not":[24],"translate":[25],"well":[26,231],"to":[27,41,50,68],"the":[28,38,52,70,124,138,210,225],"clinical":[29,65],"settings.":[30],"For":[31],"clinicians,":[32],"more":[34],"meaningful":[35],"measure":[36],"number":[39],"needed":[40],"treat":[42],"(NNT).":[43],"objective":[45],"this":[47],"analysis":[48],"assess":[51,69],"duloxetine":[55,75,110,153,165,229],"in":[56,111,209],"terms":[57],"NNT.":[59],"Data":[60],"were":[61,95,143,194,212],"obtained":[62],"from":[63,104],"nine":[64],"trials":[66],"designed":[67],"and":[72,108,132,134,145,154,175,202,235],"safety":[73],"as":[76,230,232],"treatment":[78,90,226],"for":[79,97,109,130,151,168,184,197,200,204,216],"major":[80],"depressive":[81],"disorder.":[82],"These":[83],"studies":[84],"examined":[85],"8-9":[86],"weeks":[87],"acute":[89],"duloxetine.":[92],"NNT":[93,120,148,167,215],"estimates":[94],"determined":[96],"duloxetine,":[98],"selective":[99,155,185],"serotonin":[100,156,186],"reuptake":[101,157,187],"inhibitor":[102,158],"comparators":[103],"six":[105],"multi-dose":[106],"studies,":[107],"patients":[112,163],">":[113],"or":[114,190],"=65":[115],"years":[116],"age.":[118],"was":[121,149],"based":[122],"on":[123],"Hamilton":[125],"Depression":[126],"Rating":[127],"Scale":[128],"(HAMD17)":[129],"response":[131,170],"remission,":[133,201],"improvements":[135],"defined":[136],"Clinical":[139],"Global":[140],"Impression":[141],"(CGI)":[142],"estimated":[144],"compared.":[146],"favorable":[150],"both":[152],"compared":[159,237],"placebo.":[161,239],"receiving":[164],"had":[166],"HAMD17":[169],"6.0,":[172],"remission":[173,222],"7-9,":[174],"CGI-defined":[176,205],"improvement":[177],"6-7":[178],"8":[180,203],"weeks.":[181],"NNTs":[183,208],"inhibitors":[188],"(fluoxetine":[189],"paroxetine,":[191],"20":[192],"mg/day)":[193],"around":[195],"7":[196],"response,":[198],"11":[199],"improvement.":[206],"elderly":[211],"similar.":[213],"several":[217],"measures":[218],"including":[221],"consistently":[223],"demonstrated":[224],"benefits":[227],"fluoxetine":[234],"paroxetine":[236]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}